# Self-Expanding Hydra Transcatheter Heart Valve (THV) Series Versus Balloon-Expandable Devices for Valve-In-Valve Transcatheter Aortic Valve Implantation (TAVI) for Patients With Failed Surgical Aortic Bioprosthesis.

Study · id `cardio:ct-nct07524595` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07524595](<https://clinicaltrials.gov/study/NCT07524595>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07524595

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 111 participants.

## Technical summary

Registry record NCT07524595. Randomized; no masking; primary purpose treatment. Start 2026-04 (anticipated); primary completion 2027-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 111 participants (planned count; ClinicalTrials.gov record NCT07524595, source copy `cardio:ctgov-nct07524595-2026-04-13`, retrieved 2026-10-26)
- Planned start: 2026-04 (anticipated) (ClinicalTrials.gov record NCT07524595, source copy `cardio:ctgov-nct07524595-2026-04-13`, retrieved 2026-10-26)
- Primary completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT07524595, source copy `cardio:ctgov-nct07524595-2026-04-13`, retrieved 2026-10-26)
- Completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT07524595, source copy `cardio:ctgov-nct07524595-2026-04-13`, retrieved 2026-10-26)
- Countries: Ireland (ClinicalTrials.gov record NCT07524595, source copy `cardio:ctgov-nct07524595-2026-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07524595-2026-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Self-Expanding Hydra Transcatheter Heart Valve (THV) Series Versus Balloon-Expandable Devices for Valve-In-Valve Transcatheter Aortic Valve Implantation (TAVI) for Patients With Failed Surgical Aortic Bioprosthesis.
- Acronym: REVIVAL
- Condition: AORTIC VALVE DISEASES
- Condition: Valve-in-valve Procedures
- Condition: Surgical Valve Replacement
- Condition: Valve Disease, Aortic
- Intervention (Device): Hydra THV Series
- Intervention (Device): Sapien THV Series and MyVal THV Series
- Lead sponsor: National University of Ireland, Galway, Ireland
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: National University of Ireland, Galway, Ireland (`cardio:org-national-university-of-ireland-galway-ireland`)

## Provenance

Content hash: 51aae7cf43d7505b3b84c206b96648379577490fc5ea8fa87f8788ff46285f36
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
